通过GPER激活在Dahl盐敏感大鼠中通过重叠生育前症的怀孕依赖心脏保护
Allan K N Alencar1, Kenneth F Swan2, Mistina M Manoharan1
1Department of Biomedical Engineering, Tulane University, New Orleans, Louisiana, United States.
American journal of physiology. Heart and circulatory physiology
|September 26, 2025
概括
用LNS8801激活GPER可以改善怀孕大鼠的心脏功能和降低血压,这表明怀孕前宫性心血管并发症的怀孕特异性益处. 这种G蛋白结合雌激素受体 (GPER) 激动剂显示了治疗潜力.
科学领域:
- 心血管研究研究心血管研究
- 生殖生物学 生殖生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 孕前是一个导致多器官功能障碍和心血管风险增加的妊娠障碍.
- 达尔盐敏感大鼠模型叠加孕前症,在怀孕期间表现出心脏和脏问题.
- 作为妊娠并发症的潜在治疗标,G蛋白结合雌激素受体 (GPER) 正在被探索.
研究的目的:
- 调查选择性GPER激动剂LNS8801在改善处女和孕期达尔SS/Jr大鼠心脏功能的疗效.
- 为了评估LNS8801对心脏和功能的影响,在预先怀孕的老鼠模型中.
- 为了确定GPER激活的心脏保护作用是否依赖于怀孕.
主要方法:
- 达尔SS/Jr老鼠被随机分为处女和孕妇组,用载体或LNS8801.1.治疗.
- 在怀孕的老鼠中,LNS8801从妊娠第9天到第20天口服.
- 用心声扫描来评估心脏功能,并测量蛋白尿.
主要成果:
- 在怀孕的老鼠中,LNS8801显著改善了心和腹功能,增强了应变和左心室服从性.
- 在怀孕的老鼠中,LNS8801降低了血压和蛋白尿,表明心脏保护和脏保护作用.
- 在处女大鼠中,LNS8801对心脏功能或血压没有显著影响,这表明孕期特定的GPER作用.
结论:
- 通过LNS8801激活GPER在预先怀孕症模型中显示出显著的心脏保护和抗高血压益处,但这些效应似乎取决于怀孕.
- LNS8801表现出独立于怀孕的脏保护作用,在处女和怀孕的老鼠中减少蛋白尿.
- GPER代表了一种有前途的治疗点,用于管理与妊娠前相关的心血管并发症,并有可能进行妊娠特异性干预.
更多相关视频
05:31Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
1.2K
10:44A Plate-based Cytotoxicity Assay for the Assessment of Rat Placental Natural Killer Cell Cytolytic Function
Published on: June 2, 2019
6.2K
相关概念视频
01:33Hormonal Regulation
35.7K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
35.7K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
936
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936
01:09GPCRs Regulate Adenylyl Cylase Activity
7.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.3K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K